Plasma Cell-Free DNA Methylome Profiling Predicts Response to Olaparib and Durvalumab in Recurrent IDH-mutant Gliomas: Results from a Phase II Trial

Presenting Author(s)

• 

  Yosef Ellenbogen, MD

  Neurosurgery Resident
  University of Toronto